v3.26.3
SIGNIFICANT ACCOUNTING POLICIES (Details 2) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Jun. 30, 2026
Mar. 31, 2026
Sep. 30, 2026
Sep. 30, 2025
Fair Value Warrants Liability Activity [Line Items]          
Beginning balance     $ 14,492 $ 14,492  
Issuance of liability [1],[2]       (2,972) $ (0)
Ending balance $ 23,251     23,251  
Derivative Financial Instruments, Liabilities [Member]          
Fair Value Warrants Liability Activity [Line Items]          
Beginning balance 0 $ 3,197 1,366 1,366  
Issuance of liability 2,972   2,478    
Change in fair value (737) 912 (647)    
Reclassification to equity upon modification of financing instruments   (4,108)      
Ending balance 2,235 0 3,197 2,235  
Pre Funded Warrant And Warrant Liabilities [Member]          
Fair Value Warrants Liability Activity [Line Items]          
Beginning balance $ 1,988   0 $ 0  
Issuance of liability     2,598    
Change in fair value     $ 610    
Ending balance   $ 1,988      
[1] Includes proceeds from issuance of New Notes, derivative liabilities and warrant liabilities to Oramed Pharmaceuticals Inc., a related party, of $4,397 for the six months ended June 30, 2026.
[2] See Note 9b.